- Home
- ACAD vs RNG Comparison
ACAD vs RNG Comparison
Compare ACAD & RNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACAD | RNG |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACAD | RNG |
|---|---|---|
| Price | $21.27 | $38.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 13 |
| Target Price | $30.45 | ★ $31.79 |
| AVG Volume (30 Days) | 1.6M | ★ 3.6M |
| Earning Date | 05-25-2026 | 05-22-2026 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | 69.12 | ★ 176.19 |
| EPS | ★ 2.30 | 0.48 |
| Revenue | $726,437,000.00 | ★ $2,515,142,000.00 |
| Revenue This Year | $18.52 | $5.56 |
| Revenue Next Year | $11.34 | $4.52 |
| P/E Ratio | ★ $9.55 | $80.96 |
| Revenue Growth | ★ 40.45 | 4.78 |
| 52 Week Low | $14.08 | $20.59 |
| 52 Week High | $28.35 | $42.42 |
Technical Indicators
Market Signals| Indicator | ACAD | RNG |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 59.24 |
| Support Level | $20.62 | $25.54 |
| Resistance Level | $22.75 | $40.30 |
| Average True Range (ATR) | 1.05 | 2.20 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 1.81 | 52.06 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.